Table 2. Comparison of the therapeutic effect between pemetrexed + S-1 + bevacizumab and other regimens.
| Treatment outcomes | Other regimens | Pem + S-1 + Bev | OR (95% CI) | HR (95% CI) | P |
|---|---|---|---|---|---|
| Number of patients | 67 | 21 | – | – | – |
| CR | 1 | 0 | – | – | – |
| PR | 0 | 0 | – | – | – |
| SD | 21 | 13 | – | – | – |
| PD | 45 | 8 | – | – | – |
| DCR (%) | 32.84 | 61.90 | 3.324 (1.201–9.196) | – | 0.018* |
| Events of progression or death | 65 | 17 | – | – | – |
| mPFS (m) | 2.57 (2.18–2.95) | 4.57 (2.62–6.51) | – | 0.566 (0.330–0.971) | 0.039* |
| Events of death | 41 | 13 | – | – | – |
| mOS (m) | 11.00 (7.61–14.39) | 10.17 (2.06–18.27) | – | 1.095 (0.582–2.061) | 0.777 |
*, P<0.05. CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; DCR, disease control rate; mPFS, median progression-free survival; mOS, median overall survival; OR, odds ratio; HR, hazard ratio; Pem, Pemetrexed; Bev, Bevacizumab; CI, confidence interval.